In a phase II trial led by researchers from MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non-small cell lung cancer.
The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.
